ArticleBiomaterials science2015
Micro- and Nanoparticles for Treating Cardiovascular Disease.
Article in Biomaterials science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- Nanoparticle-Based Therapeutic Strategies for Pathological Cardiac Hypertrophy: Preclinical Advances, Translational Challenges, and Future Perspectives.International journal of nanomedicine · 2026Review
- Anti-cancer Properties of Epigallocatechin-3-gallate (EGCG) and its Signaling Pathways.Current medicinal chemistry · 2025Review
- MicroRNA delivery based on nanoparticles of cardiovascular diseases.Molecular and cellular biochemistry · 2024Review
- Review
- Enzyme-Responsive Nanoparticles for the Targeted Delivery of an MMP Inhibitor to Acute Myocardial Infarction.Biomacromolecules · 2023Article
- Nuclear receptors as potential therapeutic targets in peripheral arterial disease and related myopathy.The FEBS journal · 2023Review
- Nanosystems in Cardiovascular Medicine: Advancements, Applications, and Future Perspectives.Pharmaceutics · 2023Review
- Carbon Dots for the Treatment of Inflammatory Diseases: An Appraisal ofOxidative medicine and cellular longevity · 2023Review
- Nanoparticles Targeting the Molecular Pathways of Heart Remodeling and Regeneration.Pharmaceutics · 2022Review
- Innovations in Disease State Responsive Soft Materials for Targeting Extracellular Stimuli Associated with Cancer, Cardiovascular Disease, Diabetes, and Beyond.Advanced materials (Deerfield Beach, Fla.) · 2021Review
- Lipid nanostructures for targeting brain cancer.Heliyon · 2021Review
- In vivo Cell Tracking Using Non-invasive Imaging of Iron Oxide-Based Particles with Particular Relevance for Stem Cell-Based Treatments of Neurological and Cardiac Disease.Molecular imaging and biology · 2020Review
- Nanoantioxidants: Recent Trends in Antioxidant Delivery Applications.Antioxidants (Basel, Switzerland) · 2019Review
- The interstitium in cardiac repair: role of the immune-stromal cell interplay.Nature reviews. Cardiology · 2018Review
- Multifunctional nanomedicine with silica: Role of silica in nanoparticles for theranostic, imaging, and drug monitoring.Journal of colloid and interface science · 2018Review
- (Re) Solving Repair After Myocardial Infarction.Frontiers in pharmacology · 2018Article
- Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- Enzyme-Targeted Nanoparticles for Delivery to Ischemic Skeletal Muscle.Polymer chemistry · 2017Article
- Cancer imaging using surface-enhanced resonance Raman scattering nanoparticles.Nature protocols · 2017Article
- Designing Acellular Injectable Biomaterial Therapeutics for Treating Myocardial Infarction and Peripheral Artery Disease.JACC. Basic to translational science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Cardiovascular disease, including myocardial infarction (MI) and peripheral artery disease (PAD), afflicts millions of people in Unites States. Current therapies are insufficient to restore blood flow and repair the injured heart or skeletal muscle, respectively, which is subjected to ischemic damage following vessel occlusion. Micro- and nano-particles are being designed as delivery vehicles for growth factors, enzymes and/or small molecules to provide a sustained therapeutic stimulus at the injured tissue. Depending on the formulation, the particles can be injected directly into the heart or skeletal muscle, or accumulate at the site of injury following an intravenous injection. In this article we review existing particle based therapies for treating MI and PAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.